SCHEMBL183901

SCHEMBL183901

Brc1ncc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
GPR3 P46089 1/20 0.46
EGFR P00533 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
ACHE P22303 1/20 0.44
CYP1A2 P05177 6/20 0.43
TDP1 Q9NUW8 1/20 0.42
HTR3A P46098 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
BIRC5 O15392 1/20 0.39
NCF1 P14598 1/20 0.38
NOS2 P35228 1/20 0.38
BACE1 P56817 1/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
NPC1 O15118 1/20 0.37
NQO2 P16083 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014844 1.00 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL28142768 0.82 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL1672650 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL30198446 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL30527184 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL10707622 0.73 KDM4E (0.43) KDM4EGPR3EGFRALDH1A1MAPT
SCHEMBL1461279 0.73 BACE1 (0.48) KDM4EALDH1A1MAPTCYP1A2BACE1
SCHEMBL30839232 0.73 BACE1 (0.48) KDM4EALDH1A1MAPTCYP1A2BACE1
SCHEMBL15638042 0.73 ALDH1A1 (0.48) KDM4EGPR3ALDH1A1MAPTCYP1A2
SCHEMBL24767902 0.73 LMNA (0.61) KDM4EGPR3ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803442-A Method for removing metals from hydrocarbons PETROLIAM NASIONAL BERHAD 2012-11-28 CN claimed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US claimed
US-20040044204-A1 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-04 US claimed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN claimed
CN-1474816-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN claimed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP claimed
EP-1318985-A2 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP claimed
WO-2002024666-A2 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO claimed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO claimed
EP-4676600-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF Deliver Therapeutics, Inc. (US) 2026-01-14 EP disclosed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
WO-2025095563-A1 NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME 주식회사 진웅산업 2025-05-08 WO disclosed
WO-2025078984-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS KRAS DEGRADERS AURIGENE ONCOLOGY LIMITED (IN) 2025-04-17 WO disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
EP-0637300-B1 ANTIPROLIFERATIVE QUINAZOLINES AGOURON PHARMA (US) 2001-09-05 EP disclosed
US-5885996-A AN ENZYME INHIBITORS OF THYMIDYLATE SYNTHASE WORKS AS BACTERICIDES, FUNGICIDES INHIBITING YEASTS, FUNGI AGOURON PHARMACEUTICALS, INC. (US) 1999-03-23 US disclosed
US-5707992-A MICROBIOCIDES, ANTITUMOR AGENTS AGOURON PHARMACEUTICALS, INC. (US) 1998-01-13 US disclosed
US-5430148-A Antiproliferative quinazolines AGOURON PHARMACEUTICALS, INC. (US) 1995-07-04 US disclosed
EP-0637300-A1 ANTIPROLIFERATIVE QUINAZOLINES AGOURON PHARMACEUTICALS, INC. (US) 1995-02-08 EP disclosed
WO-1993020055-A1 ANTIPROLIFERATIVE QUINAZOLINES AGOURON PHARMACEUTICALS, INC. (US) 1993-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044204-A1 4-amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 KDM4E 3578/4885GPR3 23/4885EGFR 1117/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KDM4E 3399/4885GPR3 2239/4885EGFR 1/4885
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 KDM4E 4808/4885GPR3 138/4885EGFR 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.